BEIJING, 20 March 2026 – A leading Beijing-backed brain-computer interface (BCI) developer has acknowledged it is approximately three years behind Neuralink, highlighting both the rapid progress of US neurotechnology and China’s accelerating push to close the gap in one of the world’s most advanced medical frontiers.
According to executives at NeuCyber Neurotech, a startup affiliated with the Chinese Institute for Brain Research, its most advanced implant, the Beinao-2, remains in the animal testing phase, while Neuralink has already moved ahead with human trials involving more than 20 patients.
Technology Gap Still Significant
NeuCyber’s leadership conceded that Neuralink currently holds a meaningful technological edge, particularly in surgical precision and deployment speed. Neuralink’s system uses a specialised robotic platform capable of implanting hundreds of electrodes into the brain within minutes, a capability that Chinese developers are still working toward.
By contrast, NeuCyber’s next-generation implant must still pass multiple stages:
- Large-scale animal testing
- Early feasibility trials
- Full clinical trials
This process is expected to delay widespread human application by several years.
China Still Advancing Rapidly
Despite the lag, China is making measurable progress in the BCI space.
NeuCyber has already implanted its earlier Beinao-1 device, a semi-invasive brain chip, in seven human patients, including individuals with paralysis who have shown improved motor control and the ability to interact with digital systems.
The company aims to expand trials to 50 patients within 2026, positioning itself to build one of the largest datasets globally for brain-computer interfaces.
At the national level, Beijing is aggressively backing the sector:
- BCIs have been designated a strategic industry in China’s latest five-year plan
- Government funding of around 200 million yuan (~US$29 million) has been directed to NeuCyber
- China recently approved the world’s first commercial BCI implant device for medical use
Neuralink’s Head Start
Neuralink’s advantage lies in both timing and execution.
The company began human trials earlier and has rapidly scaled clinical testing, with dozens of participants already enrolled.
Its fully implantable system, combined with automated surgical techniques, allows faster deployment and higher data throughput, giving it a clear edge in real-world application.
A Strategic Tech Race Beyond Healthcare
The competition between China and the US in BCI technology is not just medical, it is increasingly geopolitical and economic.
Brain-computer interfaces are seen as a next-generation platform technology, with applications including:
- Treatment of paralysis and neurological disorders
- Human-machine interaction
- AI-enhanced cognition
China is betting that its scale, including a large patient base and strong manufacturing ecosystem, will allow it to catch up quickly, even if it currently trails in cutting-edge innovation.
Experts believe widespread adoption of BCI technology in China could emerge within three to five years, as products mature and regulatory pathways become clearer.
The Bigger Picture
The admission of a three-year gap highlights a broader reality in the global tech race:
- The US still leads in breakthrough innovation
- China is rapidly advancing in commercialisation and scale
As both sides accelerate development, the BCI sector is shaping up to be one of the most strategically important battlegrounds in the future of technology.
The Bottom Line
China may be behind Neuralink today, but it is moving fast.
With strong state backing, expanding clinical trials and growing industrial capacity, the race to connect the human brain to machines is entering a new phase, one defined not just by innovation, but by execution and scale.
